Table 2.
Agents used in the clinic to stimulate immunogenic functions of DCs in cancer as monotherapy or in combination.
| Agonist | Cancer Type(s) | Phase(s) | Interventions | Trials | |
|---|---|---|---|---|---|
| FLT3L | CDX-301 | Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma | I/II | Radiation, Poly ICLC, Pembrolizumab | NCT03789097 |
| CDX-301 | Non-Small Cell Lung Cancer | II | Radiation | NCT02839265 | |
| CDX-301 | Colorectal Cancer, Metastatic Cancer | I | - | NCT00003431 | |
| Ad-hCMV-TK and Ad-hCMV-Flt3L | Malignant Glioma, Glioblastoma Multiforme | I | - | NCT01811992 | |
| CDX-301 | Non-Small Cell Lung Cancer Lung Cancer |
I/II | Anti-CD40 Agonist Antibody, SBRT | NCT04491084 | |
| CDX-301 | Stage IV Melanoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, Recurrent Melanoma | II | gp100, MART-1, Montanide ISA-51 tyrosinase peptide |
NCT00019396 | |
| CDX-301 | Kidney Cancer, Melanoma (Skin) | I | Recombinant CD40-ligand | NCT00020540 | |
| CDX-301 | Cutaneous, Mucosal and Ocular Melanoma | II | DEC-205/NY-ESO-1, Fusion Protein CDX-1401, Neoantigen-based, Melanoma-Poly-ICLC Vaccine | NCT02129075 | |
| CDX-301 | Melanoma, Non Small Cell Lung Cancer and others | I | CDX-1140, Pembrolizumab, Chemotherapy |
NCT03329950 | |
| CDX-301 | Breast Cancer | I | Anti-CD40 Agonist, Poly ICLC, Radiation |
NCT04616248 | |
| CDX-301 | Breast Cancer | I/II | Filgrastim, Thrombopoietin, Interleukin-3 | NCT00006225 | |
| TLR2 | CBLB612 | Breast Cancer | II | - | NCT02778763 |
| TLR4 | GLA-SE | Colorectal Cancer Metastatic | I | FOLFOX, Nivolumab, Ipilimumab | NCT03982121 |
| GSK1795091 | Neoplasms | I | GSK3174998, GSK3359609, Pembrolizumab | NCT03447314 | |
| GSK1795091 | Neoplasms | I | - | NCT02798978 | |
| GLA-SE | Melanoma | I | MART-1 Antigen | NCT02320305 | |
| GLA-SE | Soft Tissue Sarcoma | I | Radiation | NCT02180698 | |
| GLA-SE | Merkel Cell Carcinoma | I | - | NCT02035657 | |
| OM-174 | Neoplasms | I | - | NCT01800812 | |
| TLR3 | Hiltonol | Melanoma | I/II | NY-ESO-1 protein, Montanide | NCT01079741 |
| Hiltonol | Head and Neck Squamous Cell Carcinoma, Breast and others | I/II | Durvalumab, Tremelimumab | NCT02643303 | |
| Hiltonol | Ovarian cancer and others | I | OC-L, Montanide | NCT02452775 | |
| Hiltonol | Ovarian cancer | I | Oregovomab | NCT03162562 | |
| Ampligen | Ovarian cancer | I/II | OC-L, Montanide, Prevnar | NCT01312389 | |
| Hiltonol | Glioma | II | Autologous tumor lysate-pulsed DC vaccination, Tumor lysate-pulsed DC vaccination+0.2% resiquimod | NCT01204684 | |
| Hiltonol | Metastatic colon cancer Neoplasms |
I/II | Pembrolizumab | NCT02834052 | |
| Hiltonol | Glioma | II | Bevacizumab, Peptide Vaccine, Poly-ICLC as immune adjuvant, Keyhole limpet hemocyanin |
NCT02754362 | |
| TLR7 | RO7119929 | Hepatocellular Carcinoma, Biliary Tract Cancer, Secondary Liver Cancer, Liver Metastases | I | Tocilizumab | NCT04338685 |
| SHR2150 | Neoplasms | I/II | Chemotherapy, PD1 Ab, CD47 Ab | NCT04588324 | |
| Imiquimod (R837) | Breast Cancer | II | - | NCT00899574 | |
| Melanoma and others | I | PD-1 Antibody Blockade | NCT04116320 | ||
| Breast Cancer | I/II | Cyclophosphamide, Radiation | NCT01421017 | ||
| High Grade Cervical Intraepithelial Neoplasia | I | Topical Fluorouracil | NCT03196180 | ||
| DSP-0509 | Neoplasms | I/II | Pembrolizumab | NCT03416335 | |
| MEDI9197 | Neoplasms | I | Durvalumab | NCT02556463 | |
| Resiquimod | Neoplasms | I | NY-ESO-1, Montanide ISA®-51 VG | NCT00821652 | |
| 852A | Breast Cancer and others | II | - | NCT00319748 | |
| NJH395 | NON-breast HER2+ Cancers | I | - | NCT03696771 | |
| BNT411 | Neoplasms | I/II | Atezolizumab, Carboplatin, Etoposide | NCT04101357 | |
| TQ-A3334 | Non-Small Cell Lung Cancer | I/II | Anlotinib | NCT04273815 | |
| NKTR-262 | Melanoma and others | I/II | Bempegaldesleukin, Nivolumab | NCT03435640 | |
| BCDC-1001 | Breast Cancer, Gastric Cancer | I/II | Pembrolizumab | NCT04278144 | |
| LHC165 PDR001 |
Neoplasms | I | - | NCT03301896 | |
| TLR9 | CpG | Pancreatic Cancer, Metastatic Pancreatic Cancer | I | Irreversible Electroporation, Nivolumab | NCT04612530 |
| CMP-001 | Melanoma | II | Nivolumab, [18F]F-AraG PET/CT | NCT04401995 | |
| CMP-001 | Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma | I/II | Agonistic Anti-OX40 | NCT04387071 | |
| Tilsotolimod | Advanced Neoplasms | I | Ipilimumab, Nivolumab | NCT04270864 | |
| Malignant Melanoma | II | - | NCT04126876 | ||
| SD-101 | Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC | I | Nivolumab, Radiation | ||
| SD-101 | Advanced Malignant Solid Neoplasm, Extracranial Solid Neoplasm, Metastatic Malignant Solid Neoplasm | I | Anti-OX40 Antibody BMS 986178 | NCT03831295 | |
| CMP-001 | Melanoma | II | Nivolumab | NCT03618641 | |
| CMP-001 | Colorectal Neoplasms Malignant, Liver Metastases | I | Radiation, Nivolumab, Ipilimumab | NCT03507699 | |
| IMO-2125 | Metastatic Melanoma | III | Ipilimumab | NCT03445533 | |
| CMP-001 | Advanced Cancers | II | Avelumab, Utomilumab, PF-04518600, PD 0360324 | NCT02554812 | |
| EMD 1201081 |
Head and Neck Squamous Cell Carcinoma | I | 5-FU, Cisplatin, Cetuximab | NCT01360827 | |
| EMD 1201081 |
Head and Neck Squamous Cell Carcinoma | II | Cetuximab | NCT01040832 | |
| IMO-2055 | Colorectal Cancer | I | Cetuximab, FOLFIRI | NCT00719199 | |
| CpG-7909 | Esophageal Cancer | I/II | URLC10-177, TTK-567 | NCT00669292 | |